Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting

Clinical Microbiology and Infection

Volumn 11, Issue 11, 2005, Pages 887-892

  Juan, C ^a   Gutierrez, O ^a   Oliver, A ^a   Ayestaran J I ^a   Borrell, N ^a   Perez J L ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Antibiotic resistance; Intensive care unit; Molecular epidemiology; Pseudomonas aeruginosa; Resistance development; Selection of resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NALIDIXIC ACID; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONAL VARIATION; EPIDEMIC; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 27544473088     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01251.x     Document Type: Article

References (24)

1. Lynch JP. Hospital-acquired pneumonia: risk factors, microbiology and treatment. Chest 2001; 119(suppl 2): 373-384.
2. George DL, Falk PS, Wunderink RG et al. Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am J Respir Crit Care Med 1998; 158: 1839-1847.
3. Spencer RC. Epidemiology of infection in ICUs. Intens Care Med 1994; 20(suppl 4): 2-6.
4. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
5. Cantón R, Pérez-Vázquez M, Oliver A et al. Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing. J Clin Microbiol 2000; 38: 1339-1346.
6. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. Wayne, PA: NCCLS, 2000.
7. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2239.
8. Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital-acquired infection in the ICU patient. Crit Care Med 1982; 10: 355-357.
9. Chandrasekar PH, Kruse JA, Matthews MF. Nosocomial infection among patients in different types of intensive care units at a city hospital. Crit Care Med 1986; 14: 508-510.
10. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003; 361: 2068-2077.
11. Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003; 9: 413-423.
12. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa VIM-1, a novel transferable metallo-beta-lactamase. Clin Infect Dis 2000; 31: 1119-1125.
13. Tsakris A, Pournaras S, Woodford N et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000; 38: 1290-1292.
14. Luzzaro F, Mantengoli E, Perilli M et al. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase. J Clin Microbiol 2001; 39: 1865-1870.
15. Hocquet D, Bertrand X, Kohler T, Talon D, Plesiat P. Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother 2003; 47: 1887-1894.
16. Baquero F. From pieces to patterns: evolutionary engineering in bacterial pathogens. Nat Rev Microbiol 2004; 2: 510-518.
17. Bergmans DC, Bonten MJ, van Tiel FH et al. Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax 1998; 53: 1053-1058.
18. Bertrand X, Thouverez M, Talon D et al. Endemicity, molecular diversity and colonisation routes of Pseudomonas aeruginosa in intensive care units. Intens Care Med 2001; 8: 1263-1268.
19. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-1253.
20. Gutiérrez O, Juan C, Pérez JL, Oliver A. Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients. Antimicrob Agents Chemother 2004; 48: 3573-3575.
21. Thuong M, Arvaniti K, Ruimy R et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. J Hosp Infect 2003; 53: 274-282.
22. Weinstein RA. Epidemiology and control of nosocomial infections in adult intensive care units. Am J Med 1991; 91(suppl 3B): 179-184.
23. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modelling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004; 48: 125-130.
24. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 40(suppl 2): S99-S104.